AEON Biopharma Shifts Strategic Focus: Pioneers Biosimilar Pathway for ABP-450 with Proactive Phase 3 Trials and Promising Results AbstractAEON Biopharma is set to recalibrate its strategic direction toward developing biosimilars with a focused effort on ABP-450 through a 351(k) pathway. Scheduled to initiate a head-to-head comparative Phase 3 study with BOTOX? for cervical dystonia (CD) in Q3 2024, AEON shows promising preliminary results. Additionally, AEON has delivered encouraging clinical and preclinical data on ABP-450 not only for CD but also for Post-Traumatic Stress Disorder (PTSD). This article delves into the strategic realignment, clinical data, and the potential impact of ABP-450 as a biosimila...

AEON Biopharma's ABP-450 Fails to Meet Primary Endpoint in Preventive Treatment of Chronic Migraine Trial

This article pr...

AEON Biopharma's Groundbreaking Potential in Preventive Migraine Treatment Shows Promise in Fourth Quarter and Full Year 2023 Financial Results

In an exciting development for the field of migraine treatment, AEON Biopharma recently announced its fourth quarter and full year 2023 financial results along with a successful end-of-Phase 2 meeting with the FDA. The company s proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraines have now received alignment on design and endpoints, further fueling hopes for a breakthrough treatment. This article delves into the significance of AEON Biopharma s achievements, the potential impact on migraine patients, and the implications for the pharmaceutical industry.Understanding the Burden of Migraines:Migraine is a debilitating neurological condition affecting millions worl...

AEON's Stock Performance relative to it's Customers

AEON's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Aeon Biopharma inc	3.44	0.00	10.55	11
SUBTOTAL	0.00	0.00	0.00	-

Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com